IN THE CLAIMS

The following listing replaces all prior listings and versions of the claims. The deletion of subject matter from any claims or the cancellation of any claim is effected without prejudice.

1. (Withdrawn) A method for the treatment, amelioration and/or prophylaxis of a neurological condition which comprises the administration of an effective amount of a compound of Formula I:



I

in which

R is O or S;

R^1 is independently selected from H, optionally substituted alkyl, optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted aryl; optionally substituted heterocyclyl; an antioxidant; a targeting moiety; CN; halo; CF_3 ; SO_3H ; and OR^2, SR^2, SOR^2, SO_2R^2, NR^2R^3, $(CH_2)_nNR^2R^3$, $HCNOR^2$, $HCNNR^2R^3$, $CONR^2R^3$, $CSNR^2R^3$, $NCOR^2$, $NCSR^2$, COR^2, CO_2R^2, CSR^2 or $SO_2NR^2R^3$ in which R^2 and R^3 are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, an antioxidant or a targeting

moiety and n is an integer of 1 to 10;

X is independently selected from CH, CO, N and NH;

Z is independently selected from CH, CO, N, NH and O;

Y is absent or together with the ring to which it is attached forms a 5-or 6-membered optionally substituted aryl or a 5-or 6-membered optionally substituted heterocyclyl;

m is an integer from 1 to 3; and

p is an integer from 1 to 4,

salts, hydrates, solvates, derivatives, pro-drugs, tautomers and/or isomers thereof to a subject in need thereof, with the provisos that:

(i) at least one of X and Z is other than CH; and

(ii) phanquinone or tautomers thereof are excluded i. e. , when R is O, R^1 at position 7 is OH, X is CH and Y is absent, then Z is not

;

(iii) when R is O, Y is absent, Z is CH, X is CH other than at position 3 where X is N, m is 2 and R^1 is



at position 3, then R^1 at position 2 is not



or



; and

(iv) clioquinol, i.e., when R is O, Y is absent, Z and X are CH and m is 2, then R^1 at position 5 is not chloro and R^1 at position 7 is not iodo.

2. (Withdrawn) A method according to Claim 1, in which the compound of formula I is selected from the following:



8-hydroxy-4(3H)-quinazolinones;



8-hydroxy-quinazoline;



8-hydroxy-quinoxaline;



[1,6]naphthyridin-8-ol;



9-hydroxypyrimido[1,6-a]pyrimidin-4-one;



8-hydroxy-cinnoline;



6-hydroxy-phenazine;



4-hydroxy-acridine;





4,7(4,10)-phenanthrolin-5-ol;



4,7(4,10)-phenanthrolin-5-ol;





9-hydroxypyrido[1,2-a]pyrimidin-4-one;



pyrido[3,2-d]pyrimidin-4-ol;



pyrido[2-3-d]pyridazin-8-ol;



[1,7]naphthyridin-8-ol;



[1,5]naphthyridine-4,8-diol;



[1,5]naphthyridine-8-ol;



pyrido[3,4-b]pyrazin-8-ol;



pyrido[3,4-b]pyrazin-5-ol;



pyrido[4,3-d]pyrimidin-8-ol;



4-hydroxy-4a,8a-dihydro-pyrano[3,2,b]pyridin-2-one;



8-hydroxy-6*H*-[1,6]naphthyridin-5-one;



8-hydroxy-6H-[1,6]naphthyrin-5-one;



dibenzo[a,g]quinolizin-8-one; and



4-hydroxy-1*H*-pyrido[3,2-d]pyridin-2-one

in which R^1, m, n and p are as defined in Claim 1 and q is an integer of 1 or 2.

3. (Withdrawn) A method according to Claim 1 or Claim 2 in which the compound of formula I is a compound of formula IA:



IA

in which

R, R^1 and m are as defined in Claim 1;

W is CH, N or NH ;

U is CH, CO or N; and

Y' is absent together with the ring to which it is attached forms a 6 membered N-

containing optionally substituted heterocyclyl.

4. (Withdrawn) A method according to Claim 3 in which the compound of Formula IA is selected from the following:

(i) Formula Ia



Ia

in which R, R^1, m and q are as defined above;

(ii) Formula 1b



Ib

in which R, R^1, m and q are as defined in any one of Claims 1 to 3;

(iii) Formula Ic



Ic

in which R, R^1, m and q are as defined in any one of Claims 1 to 3;

(iv) Formula Id



Id

in which R, R^1, m and q are as defined in any one of Claims 1 to 3;

(v) Formula Ie



Ie

in which R, R^1, m and q are as defined in any one of Claims 1 to 3; and

(vi) Formula If



If

in which R, R^1, m and q are as defined in any one of Claims 1 to 3.

5. (Withdrawn) A method according to any one of claims 1 to 4 in which R in the compound of Formula I is O.

6. (Withdrawn) A method according to any one of claims 1 to 5 in which R^1 in the compound of formula I is halo, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkyl, OR^2, SR^2, $(CH_2)_nNR^2R^3$, $CONR^2R^3$ and $NCOR^2$ in which n, R^2 and R^3 are as defined in any one of Claims 1 to 3.

7. (Withdrawn) A method according to any one of claims 1 to 6 in which R^1 in the compound of Formula I is fluoro, iodo, chloro, optionally substituted phenyl, an optionally substituted unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, an optionally substituted saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, an optionally substituted saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, optionally substituted C_{1-4} alkyl, optionally substituted C_{2-6} cycloalkyl, optionally substituted C_{1-6} alkoxy, optionally substituted thio, $CH_2NR^4R^5$ in which R^4 and R^5 are independently selected from H and C_{1-4} alkyl or

$CONH(CH_2)_2R^6$ in which R^6 is optionally substituted heterocyclyl.

8. (Withdrawn) A method according to any one of Claims 1 to 7 in which Y in the compound of formula I is an optionally substituted phenyl, an optionally substituted unsaturated 5-or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms or an optionally substituted saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms.

9. (Withdrawn) A method according to any one of claims 1 to 8, in which the compound of Formula I is as follows:



1055



1061



1067



1049









1066





1064



1065



1053



1045



1070



1063



1069



1048







1026

10. (Withdrawn) A method according to any one of claims 1 to 9, in which the neurological condition is a neurodegenerative disorder.

11. (Withdrawn) A method according to Claim 10, in which the neurodegenerative is neurodegenerative amyloidosis.

12. (Withdrawn) A method according to Claim 10 or Claim 11, in which the neurodegenerative disorder is sporadic or familial Alzheimer's disease, amyotrophic lateral sclerosis, cataract, Parkinson's disease, Creutzfeldt-Jacob disease and its new variant associated with"mad cow"disease, Huntington's disease, dementia with Lewy body formation, multiple system atrophy, Hallerboden-Spatz disease, diffuse Lewy body disease, fatal familial insomnia, Gertsmann Straussler Sheinker disease, hereditary cerebral haemorrhage with amyloidosis-Dutch type, multiple sclerosis, tauopathies, motor neuron disease or prion diseases.

13. (Withdrawn) A method according to Claim 12, in which the neurodegenerative disorder is Parkinson's disease.

14. (Withdrawn) A method according to any one of Claims 10 to 12, in which the neurodegenerative disorder is an Aβ-related condition.

15. (Withdrawn) A method according to Claim 14, in which the Aβ-related condition is Alzheimer's disease or dementia associated with Down syndrome or one of several forms of autosomal dominant forms of familial Alzheimer's disease.

16. (Withdrawn) A method according to any one of the preceding claims which slows, reduces or arrests the cognitive decline of the subject.

17. (Withdrawn) A method according to any one of the preceding claims, which further comprises separate, sequential or simultaneous administration of another medicament.

18. (Withdrawn) A method according to Claim 17, in which the other medicament is an inhibitor of the acetylcholinesterase active site, an antioxidant, an anti-inflammatory agent or an oestrogenic agent.

19. (Withdrawn) A method according to any one of the preceding claims, in which the compound of formula I is administered orally, topically or parenterally.

20. (Withdrawn) Use of the compound of formula I as defined in any one of Claims 1 to 9, in the manufacture of a medicament for the treatment, amelioration and/or prophylaxis of a neurological condition.

21. (Withdrawn) Use of a compound of formula I as defined in any one of Claims 1 to 9 for the treatment, amelioration and/or prophylaxis of a neurological condition

22. (Currently Amended) A compound of Formula Ia ~~as defined in Claims 1 to 9 for use in the treatment, amelioration and/or prophylaxis of a neurological condition.~~



Ia

in which

R is O or S;

R^1 is independently selected from H, optionally substituted alkyl, optionally substituted

alkenyl; optionally substituted alkynyl; optionally substituted aryl; optionally substituted heterocyclyl; CN; halo; CF_3 ; SO_3H ; and OR^2, SR^4, SOR^2, SO_2R^2, NR^2R^3, $(CH_2)_nNR^2R^3$, $HCNOR^2$, $HCNNR^2R^3$, $CONR^2R^3$, $CSNR^2R^3$, $NCOR^2$, $NCSR^2$, COR^2, CO_2R^2, CSR^2 or $SO_2NR^2R^3$ in which R^2 and R^3 are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heterocyclyl, and n is an integer of 1 to 10;

R^4 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted heterocyclyl;

m is an integer from 1 to 3; and q is 1 or 2;

or pharmaceutically salts thereof or tautomers of compounds of Formula Ia,

wherein aryl is a 5 or 6-membered aryl group; heterocyclyl is a saturated or unsaturated 3 to 6-membered heterocyclyl containing at least one heteroatom selected from N, O and S,

and the optional substituent is C_{1-6} alkyl, CF_3, F, Cl, I, cyano, C_{1-6} alkoxy, aryl, heterocyclyl, amino or C_{1-6} alkylamino, with the provisos that:

(1) when R is O,

m is 2 and R^1 is



at position 3, then R^1 at position 2 is not



or



; and

(2) R^1 is located at position 5 or 7 of the ring and is halo.

23. (Withdrawn) Use of the compound of formula I as defined in any one of Claims 1 to 9, as a pharmaceutical.

24. (Withdrawn) Use according to Claim 23, in which the pharmaceutical is a neurotherapeutic or neuroprotective agent.

25. (Withdrawn) Use according to Claim 23 or Claim 24, in which the pharmaceutical is an antiamyloidogenic agent

26. (Currently Amended) A pharmaceutical or veterinary composition comprising the compound of formula [[I]] Ia ~~as defined above in any one of Claims 1 to 9,~~ according to Claim 22 and a pharmaceutically or veterinarily acceptable carrier.

27. (Original) A composition according to Claim 26 which further comprises another medicament.

28. (Original) A composition according to Claim 27, in which the other medicament is an inhibitor of the acetylcholinesterase active site, an antioxidant, an anti-inflammatory agent or an oestrogenic agent.

29-32. (Cancelled)

33. (Withdrawn) A process for the preparation of the compound of Formula II defined in Claim 29 as described herein.

34. (Withdrawn) A compound of the Formula:



35. (New) The compound according to Claim 22 in which R is O.

36. (New) The compound according to Claim 22 in which R^1 is halo, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkyl, OR^2, SR^4, $(CH_2)_nNR^2R^3$, $CONR^2R^3$ or $NCOR^2$.

37. (New) The compound according to Claim 22 in which R^1 is F, I, Cl, optionally substituted phenyl, an optionally substituted unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, an optionally substituted saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, an optionally substituted saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, optionally substituted C_{1-4} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted C_{1-6} alkoxy, optionally substituted thio, $CH_2NR^4R^5$ in which R^4 and R^5 are independently selected from H and C_{1-4} alkyl or CONH $(CH_2)_2R^6$ in which R^6 is optionally substituted heterocyclyl.

38. (New) The compound according to Claim 22 wherein R^1 is independently selected from halo, optionally substituted heterocyclyl, optionally substituted alkyl, or $(CH_2)_nNR^2R^3$.

39. (New) The compound according to Claim 22, wherein R^1 is chlorine, optionally substituted phenyl, C_{2-6} cycloalkyl, $(CH_2)NR^4R^5$, wherein R^4 and R^5 are independently selected from H and C_{1-4} alkyl is optionally substituted phenyl.

40. (New) The compound according to Claim 22 having the formula:



1055



1061



1067

41. (New) The compound according to Claim 22 wherein Cl is at position 5 or 7 of the ring.

42. (New) The compound according to Claim 22 in which halo is at positions 5 and 7 of the ring.

43. (New) The compound according to Claim 22 wherein Cl is at position 5 and 7 of the ring.